Yes, the data is hosted on a fully secure health data warehouse. In addition, we do not sell your data or your patients' data to third parties.
The use of the Predigraft application requires you to provide certain personal data in order to operate the application.
When using the application, you may be asked to provide us with your full name, date of birth, gender, title, language, email address and telephone number in order to:
The estimated GFR value must be between 0 and 300. Above 120, a message informs you that the iBox calculation will be done with a GFR of 120
The limit of 120 mL/min/1.73m² for calculating the iBox result has been established because the calculation of the iBox probabilities and the expected survival benefit at 3, 5, 7 years are unchanged above 120 mL/min/1.73m².
The Monitoring/Risk Assessment item lists the patient's iBox reports. You can click on one of the rows in the list to access the iBox report.
The date corresponds to the date entered in the "DFG-e" step when creating a report.
The pictograms correspond to :
Biological data: This icon is always present. It corresponds to the first two mandatory steps of the creation of a report: GFR-e and Proteinuria.
Graft specific anti-HLA antibody (DSA) data. This icon is present if you have entered DSA data when creating the report.
Histology data: This icon is present if you have entered data in Histology when creating the report.
You have just received an iBox alert on one of your patient's profile, what does this mean?
The iBox alert is a notification of a 5-point decrease in the 7-year graft survival percentage from the highest percentage in the year or from the last biopsy.
A 5% decrease in the probability of 7-year graft survival is a sign of patient instability and is associated with more renal graft complications/damage. By sending you a notification, the aim is to give you additional information in the management of your patient and the therapeutic decision.
This alert is generated automatically, whether the data is entered manually or automatically in the iBox.
Use Case :
In practice, Predigraft's iBox alert is intended to be used as a follow-up tool after a kidney transplant. Following an iBox alert, the doctor can, for example, prescribe additional examinations: Doppler ultrasound of the graft, examination for pyelonephritis of the graft, search for DSA, or even biopsy of the graft. This alert may also lead you to adjust the frequency of follow-up of your patients according to changes in their graft survival percentage.
Below is an example of a case where the iBox alert would have allowed an intervention by the health professional.
Patient profile :
36 year old patient - Alport syndrome - Transplanted 3.3 years ago - Last biopsy 1.3 years ago: normal, no rejection
Evolution of proteinuria and creatinine since the last biopsy:
Insidious increases in creatinine and proteinuria can be observed, but relatively small between each measurement. These progressions did not lead to medical intervention.
The patient had a biopsy on day 500 (following the development of proteinuria), which may have shown antibody-mediated rejection.
Evolution of the 7-year survival probability of the kidney graft since the last biopsy:
An iBox alert would have been triggered on day 100 (iBox at 7 years decreases by 10%).
This could have triggered an intervention by the health professional.
Predigraft is being developed using integrative BOX technology (iBox).
The iBox predicts the likelihood that the graft will still be functional at 3 years, 5 years and 7 years after assessment by healthcare staff.
Predigraft provides a detailed view of individual patient risks and allows for personalised treatment, aimed at prolonging allograft survival and improving patient well-being.
If you want more information about your predictive score, talk to your nephrologist.
Your nephrologist has asked you to weigh yourself regularly. A rapid change in weight indicates a change in the amount of water in your body.
The important thing is to always weigh yourself under the same conditions (dressed or naked, before or after eating, in the morning or in the evening...)
To ensure optimal remote monitoring by your nephrologist, you should at least weigh yourself every 15 days and report the values in your Apilife account.
To ensure optimal remote monitoring by your nephrologist, you should at least take your blood pressure every two weeks and report it in your Apilife account.
Caution : if you have a functional arteriovenous fistula,
take your blood pressure on the other arm
Your nephrologist has asked you to carry out this procedure to detect hypertension or to check the effectiveness of your antihypertensive treatment. Self-measurement of blood pressure eliminates the "white coat" effect, i.e. a temporary increase in blood pressure when taken by a doctor.
Normal blood pressure contributes to a better long-term survival of your graft and a reduction in cardiovascular risks.
Telemonitoring is another way of treating patients, with the same quality and safety requirements as traditional procedures.
It is helping medicine evolve to meet challenges such as the ageing of the population and the in-depth monitoring of chronic diseases. It aims to improve access to care and its organisation, particularly in fragile areas.
It is not intended to replace face-to-face medical procedures, but to complement them. It does not replace more usual medical practices but is a response to the challenges facing the health care system today and is integrated into the care pathway.
Apilife does not replace consultations with your nephrologist but allows for more regular follow-up.
Telemonitoring is defined by article R.6316-1 3° of the public health code. It is an act that allows a health professional to remotely interpret the data necessary for the medical follow-up of a patient and, if necessary, to take decisions relating to the management of this patient. Remote monitoring is more precisely defined as the remote monitoring of clinical or bioclinical indicators with the identification of alerts that may require medical intervention.
Its benefits :
The Experimentation of Telemedicine for the Improvement of Health Care Pathways (ETAPES) programme has been in place throughout France since 2017 to develop telemedicine activities, define a legal framework within which they can evolve and set a prefigurative pricing system for procedures.
The experiments conducted within the framework of ETAPES should make it possible to: